搜索筛选:
搜索耗时0.0638秒,为你在为你在102,285,761篇论文里面共找到 7 篇相符的论文内容
发布年度:
Growth differentiation factor 6,a repressive target of EZH2,promotes the commitment of human embryon
[期刊论文] 作者：Pend Deng,Yongxin Yu,Christine,
来源：骨研究:英文版 年份：2020
Mesenchymal stem cells(MSCs)derived from human embryonic stem cells(hESCs)have significant potential for cell-mediated bone regeneration.Our recent study reveal...
Growth differentiation factor 6, a repressive target of EZH2, promotes the commitment of human embry
[期刊论文] 作者：Pend Deng,Yongxin Yu,Christine Hong,Cun-Yu Wang,
来源：骨研究（英文版） 年份：2020
INTRODUCTIONrnMesenchymal stem cells (MSCs) are a promising source for the treatment of various bone diseases and injuries due to their self-renewal capacity an...
Study on the protective efficacy of SA 14-14-2 attenuated Japanese encephalitis against different JE
[会议论文] 作者：Xinyu Liu,Yongxin Yu,Maoguang Li,Guodong Liang,Huanyu Wang,Lili Jia,Guanmu Dong,
来源：2010年中国药学会大会生物制品研发新进展论坛暨生物制品专业委员会筹备会议 年份：2010
In China,many JE virus strains of genotype Ⅰ are isolated recent years while strains of genotype Ⅲ are still circulating.In order to understand the immunogenicity of vaccines to these new isolates of...
[会议论文] 作者：Xinyu Liu,Yongxin Yu,Hongshan Xu,Guangzhi Yue,Lihong Yang,Guanmu Dong,Yuhua Li,Lili Jia,
来源：2013中国药学大会暨第十三届中国药师周 年份：2013
Japanese encephalitis (JE) is the main cause of viral encephalitis in many countries of Asia.The infection is mosquito-borne and caused by the JE virus.The control of JE is based essentially by immuni...
,The structure differences of Japanese encephalitis virus SA14 and SA14-14-2 E proteins elucidate th
[期刊论文] 作者：Xinyu Liu,Xin Zhao,Rui Na,Lili Li,Eberhard Warkentin,Jennifer Witt,Xu Lu,Yongxin Yu,Yuquan Wei,Guohong,
来源：蛋白质与细胞 年份：2019
Dear Editor,Japanese encephalitis (JE) is a mosquito-boe acute neurological infectious disease caused by the Japanese encephalitis virus (JEV).Globally,68,000 c...
[期刊论文] 作者：杨峤,孙建国,Jiaoyang GU,Kai NIU,Xianlan ZHAO,Linpeng ZHENG,Zihan XU,Yongxin YU,Feng LI,Lingxin MENG,Zhengtang,
来源：中国肺癌杂志 年份：2021
背景 免疫检查点抑制剂(immune checkpoint inhibitors,ICIs)具有良好疗效已成为恶性肿瘤治疗领域备受瞩目的翘楚.然而,仅有小部分患者获得长期临床获益.如何选择生物标志物来筛查ICIs治疗优势人群仍是一大热点.方法 收集51例晚期恶性肿瘤患者的肿瘤组织和配对......
[期刊论文] 作者：显示全部作者", class=",showAll",>,,Linpeng ZHENG,Zihan XU,Yongxin YU,Feng LI,Lingxin MENG,Zhengtang,
来源：中国肺癌杂志 年份：2021
背景免疫检查点抑制剂（immune checkpoint inhibitors, ICIs）具有良好疗效已成为恶性肿瘤治疗领域备受瞩目的翘楚。然而,仅有小部分患者获得长期临床获益。如何选择生物标志物来筛查ICIs治疗优势人群仍是一大热点。方法收集51例晚期恶性肿瘤患者的肿瘤组织和配对......
相关搜索：
